Cancer Research UK partners with ORIC Pharmaceuticals to bring first-in-class CIP2A-targeted therapy into clinical trials
Cancer Research UK have signed an agreement with ORIC Pharmaceuticals, Inc. to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Under the agreement, Cancer Research UK’s Centre for […]
Earlier detection of liver cancer thanks to improved patient monitoring at Medway Maritime Hospital
More patients at risk of developing liver cancer are receiving potentially life-saving monitoring at Medway Maritime Hospital thanks to the introduction of a new digital tracking system. An internal audit […]
Clearing ‘immune fog’ could stop lung cancer years before diagnosis
Scientists funded by Cancer Research UK have discovered a “rising fog” that may cloud the immune system’s ability to detect tumours, potentially helping lung cancer develop years before diagnosis. The […]
Landmark lung cancer research carried out at Royal Papworth Hospital given special commendation in 2026 NIHR Impact Prizes
A landmark lung cancer research trial carried out at Royal Papworth Hospital NHS Foundation Trust has been given a special commendation for its scientific and economical impact. The research explored […]
Research into rare breast cancer type highlights importance of personalised treatment
New research has found that a rare form of triple-negative breast cancer has a generally favourable long-term prognosis and may not require the same treatment approach as more common triple-negative […]
People with localised prostate cancer could benefit from advanced radiotherapy as an alternative to surgery while maintaining long-term cancer control
People with localised, low-to-intermediate-risk prostate cancer could benefit from SBRT, a highly targeted form of radiotherapy, which research suggests may be just as effective as radical prostatectomy (surgical removal of […]
52North raises £3.2 million to transform urgent cancer care, with funding co-led by Macmillan Cancer Support and Hargreave Hale AIM VCT
52North, the University of Cambridge spin-out behind the Aster™ biomarker platform, has secured £3.2 million in new funding to accelerate its mission to help transform urgent cancer care and bring […]
Prostate cancer fitness programme protects men from side effects of treatment, study finds
A landmark NHS trial involving Sheffield Teaching Hospitals NHS Foundation Trust shows a purpose-designed prostate cancer lifestyle programme protected men from side effects of treatment, is low-cost, and can be […]
Cancer Research Horizons partners with Nexomic to advance AI-powered precision oncology
Cancer Research Horizons, the innovation engine of Cancer Research UK, has announced a partnership with Nexomic, a precision oncology TechBio company developing AI-powered tools to improve cancer care. The agreement […]
Cancer incidence remains higher in people with type 2 diabetes, with the gap widening in recent years
A nationwide study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found that […]
